<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Transfusion-related morbidity is an emerging challenge in chronically transfused patients with low-risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>In these patients, transfusion-induced <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> may represent a leading medical problem </plain></SENT>
<SENT sid="2" pm="."><plain>However, although iron-chelating drugs are available, little is known about optimal diagnostic tools, predisposing factors, and the optimal management of these patients </plain></SENT>
<SENT sid="3" pm="."><plain>In the current article, we provide recommendations for the diagnosis, prevention and treatment of <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and propose treatment response criteria </plain></SENT>
<SENT sid="4" pm="."><plain>Consensus criteria and resulting recommendations were discussed and formulated by members of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> platform of the Austrian Society of Haematology and <z:hpo ids='HP_0002664'>Oncology</z:hpo> in a series of meetings and conferences in 2006 and 2007 </plain></SENT>
<SENT sid="5" pm="."><plain>These recommendations should facilitate and assist in recognition of <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e>, selection of patients, timing of treatment, drug selection and the measurement of treatment responses </plain></SENT>
</text></document>